EHA Unplugged

Join us for this captivating interview with Prof Kirsten Grønbæk from University of Copenhagen in Denmark, as she discusses her outstanding career in the field of hematology, both in research and in the clinics. Listen to how the interests of Prof Grønbæk evolved, leading her from the initial focus on epigenetics in lymphomas to MDS in the later years of her career. Prof Grønbæk reflects on the current developments in MDS and her tips for the leading a successful research team in hematology. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Kirsten GrønbækLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, we sit down with Prof. Maria Domenica Cappellini from the University of Milan in Italy, as she discusses her inspiring career as a hematologist specializing in the management of patients with thalassemia. Listen to the compelling story of how Prof. Cappellini’s interest in thalassemia started and how her relentless stride for the best possible care for her patients has helped to transform the way this disease is managed. Tune in to hear prof. Cappellini’s words of advice for the younger generation of hematologists interested in the field of thalassemia.  Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Maria Domenica CappelliniLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Explore the latest breakthroughs in gene therapy for sickle cell disease and beta thalassemia with Dr. Stefano Rivella, hematologist and research faculty at Children's Hospital of Philadelphia.  In this episode, Dr. Rivella discusses the science behind FDA-approved therapies, compares gene addition and gene editing approaches, and shares insights on clinical safety, efficacy, and future innovations like in vivo gene therapy.  Learn about the challenges of access, cost, and global equity, and discover how evolving technologies could transform treatment for patients worldwide. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr Stefano RivellaLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this insightful interview with prof. Hartmut Döhner from University Hospital Ulm in Germany who tells about most recent developments in the management of older and unfit patients with AML. Prof. Döhner discusses all key aspects of the management including assessing patient fitness, genetic risk classification, and the choice of treatment, among which also the emerging therapies. Tune in, to hear about the most relevant recommendations for the clinical decision making while treating older unfit patients with AML.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Hartmut Döhner, University Hospital Ulm, GermanyLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join EHA President prof. Konstanze Döhner from University Hospital Ulm in Germany who discusses the most recent developments in the management of young and fit patients with AML. Tune in to hear about the diagnostic workup, risk stratification, treatment and the evolving role of measurable residual disease (MRD) measurements in clinical decision making in this group of patients. Prof. Döhner also shares her thoughts on the future of the treatment landscape for AML.  Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Konstanze DöhnerLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Listen as Prof. Christian Chabannon from Aix Marseille Université in France who tells about GoCART Coalition in this new podcast episode. The main goal of this coalition, which unites expertise from many fields, is to promote access to novel cellular therapies, such as CAR T-cells. Prof. Chabannon explain how GoCART is working on reaching this goal by generating new clinical insights, improving standards of care, providing education and building policy. Tune in to learn more about the impact of this coalition on healthcare today and in the future.      Stay tuned for future episodes!   Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof. Christian ChabannonLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Jan Geissler from Germany tells about his work as a patient advocate in the field of hematological malignancies. As a cancer survivor, patient advocate and patient engagement expert, Jan has been working tirelessly for many years in organizations such as European Patients Academy (EUPATI), Patvocates and many others. Listen to Jan’s passionate call for a collaborative spirit to achieve the best outcomes for patients. Tune in to hear his views on patient advocacy and the impact it has on patient care.   Stay tuned for future episodes!   Guest: Jan Geissler, Patient Advocate, Germany Host: Isabel Olivera-Martinez, PhD, Medical Writer   Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Prof. Maria Themeli tells about most recent developments in the field of “off-the-shelf” CAR T-cells. As the clinical success of advanced cellular therapies is growing, so is the need for broader access to these treatments. Listen as Prof. Themeli summarize the state-of-the-art technology that aims to generate “off-the-shelf” CAR T-cells from sources such as induced pluripotent stem cells (iPSCs) and how this approach may offer a feasible strategy to improve clinical outcomes and reduce the costs of advanced cellular therapies in the future.    Stay tuned for future episodes!   Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Maria ThemeliLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join dr. Carmen Sanges from University Clinic Würzburg in Germany as she tells us about AIDPATH. This collaborative initiative is dedicated to improving access to advanced cellular therapies by employing artificial intelligence (AI) in the production process. Listen to dr. Sanges explain how AI technology is used to integrate patient-specific information and biomarkers to optimize CAR-T therapy. Tune in to hear about the current approaches and future directions of this cutting-edge technology. Stay tuned for future episodes!   Host: Isabel Olivera-Martinez, Medical Writer Guest: Dr Carmen SangesLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this inspiring interview with prof. Elizabeth Macintyre from Université Paris Cité in France who tells us about her professional journey in hematology. Listen to prof. Macintyre discuss her views on the current state and future directions of advanced diagnostics in malignant hematology and their implications for healthcare management and the training of young specialists. Tune in to hear how Biomedical Alliance may impact future policies through “trans-European” approaches. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Elizabeth MacintyreLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join Professor Kirsten Gronbaek and Professor Uwe Platzbecker as they discuss the complexities behind the classification and prognostication of low-risk myelodysplastic syndromes (MDS). They dive into the historical context of MDS classification, the evolution of prognostic indexes such as IPSS and IPSSM, and the implications of recent molecular findings.  This conversation highlights the challenges in defining "low-risk" MDS, the role of genetic mutations in prognosis, and the considerations for treatment strategies, including the potential for stem cell transplantation.   Host: Professor Kirsten Gronbaek, University of Copenhagen, Denmark Guest: Professor Uwe Platzbecker, University Clinic of LeipzigLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join host Professor Kirsten Gronbaek and guest Professor Arjan van de Loosdrecht as they dive into the complexities of measurable residual disease (MRD) monitoring in myelodysplastic syndromes (MDS) and myeloid cancers. Professor van de Loosdrecht explains the transition from minimal to measurable residual disease, the significance of MRD in predicting disease outcomes, and the various techniques used for MRD detection.   Listen as they explore the challenges and potential strategies for MRD monitoring in MDS, and the implications for treatment decisions. This episode is a must-listen for anyone interested in the latest advancements in hematology and the future of MRD monitoring in MDS.  Tune in to EHA Unplugged to gain valuable insights and stay updated with the latest research and clinical practices in hematology.Host: Prof Kirsten GronbaekGuest: Prof Arjan van de LoosdrechtLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, we sit down with prof. Martin Dreyling from the Ludwig-Maximilians-University in Munich who talks about his professional journey in hematology as a clinician and a researcher. Listen to prof. Dreyling as he recalls his contributions to the field of lymphoma, and in particular mantle cell lymphoma, that resulted in novel therapeutic approaches. The ongoing emphasis on the cross-border teamwork in clinical trials and the importance of European cooperation highlights the impact that these initiatives had on prof. Dreyling’s career. Tune in to hear his thoughts about the future directions in lymphoma treatment and collaborative clinical research in general.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: prof. Martin DreylingLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, prof. Kirsten Gronbaek and dr. Shahram Kordasti discuss the role of immune dysfunction in MDS. With the improving understanding of complex pathophysiology of MDS, the major role of the immune system in this process is becoming increasingly apparent. Listen to dr. Kordasti discuss the multifactorial interactions between the malignant clones and the inflammatory environment, manifesting in elements of autoimmunity and elements of autoinflammation in MDS. As the complexity of immunophenotypes observed in MDS is being unraveled, the need to include immunophenotypic factors in the prognostic scores is growing. Tune in to hear dr. Kordasti’s and prof. Gronbaek’s thoughts on the future of prognostication, the more comprehensive approach for patient stratification designed to predict therapy responses and the future of immunotherapy in MDS.Host: Prof Kirsten GronbaekGuest: Dr Shahram KordastiLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this interview, dr. Maria del Mar Mañu Pereira from Vall d’Hebron Research Institute in Spain talks about the Rare Anemia Disorders European Epidemiological Platform (RADeep). RADeep is an initiative of ERN-EuroBloodNet and functions as an umbrella for both new and already existing European patients' registries in rare anemia disorders.  Listen to dr. Mañu Pereira talk about the history of RADeep from its early days until today and about its ambitious goals to advance research and promote best practices in care for RAD patients across Europe. You will hear about the milestones achieved, current research, and how RADeep registry and the ENROL (European Rare Blood Disorders Platform) initiative complement each other to achieve optimal health outcomes for RAD patients.Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Maria del Mar Mañu PereiraLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Prof. Antonio Almeida from Hospital da Luz in Lisbon takes us through his professional journey in hematology as a clinician and educator, and his current role as the President of EHA. Listen to prof. Almeida recount his professional path that allowed him to experience various facets of hematological clinical practice in the UK and Portugal. Alongside his career as a hematologist, prof. Almeida cultivated a growing love for education, where he tries to employ student-centered techniques to enhance educational experiences. Tune in to hear how prof. Almeida describes his journey to becoming the President of EHA and what he sees as today’s most significant challenges in hematology and what solutions he has in mind to address those. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof. Antonio AlmeidaLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options. He uses the example of targeting NLRP3/IL-1 axis in low-risk MDS to highlight the need of understanding the underlying cellular biology to translate that knowledge into clinical approaches. He also discusses the concept of possibly targeting both non-clonal and clonal compartments for better patient outcomes in the future. Tune in, to hear about other future directions in treatment of MDS, such as recent developments in CAR T-cell approaches and about the central role that allo-transplantation is likely to keep in the treatment of high-risk MDS. You will also hear about the potential link between inflammation and fatigue, which is clinically highly relevant, but as yet an unsolved issue in MDS.  Host: prof. Kirsten GronbaekGuest: prof. Dominik WolfLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. If you want to know more: https://www.nature.com/articles/s41746-024-01076-x Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Dr. Jan Moritz MiddekeLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic process. The conversation also touches on the potential of artificial intelligence in diagnostics, the prognostic value of genetic mutations, and the importance of considering germline disorders in MDS. This episode is a must-listen for healthcare professionals seeking to deepen their understanding of MDS diagnostics. Host: Prof Kirsten GrønbækGuest: Dr Onima ChowdhuryLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this insightful interview with prof. Brian Huntly from the University of Cambridge who tells about his professional journey in hematology as a clinician, scientist and educator. Listen to prof. Huntly discuss his important contributions to the field of leukemia stem cell biology in the context of current understanding of cell biological hierarchies and leukemia development. Prof. Huntly also touches on the concepts of early interception and tumor-specific and tumor-nonspecific areas to personalized medicine. Tune in to hear how prof. Huntly combines his work in the fields of science and clinical medicine and what his recommendations are for younger colleagues, who are in the early stages of their careers. Host: Isabel Olivera-Martinez, PhD, Medical Writer Guest: Prof Brian Huntly Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe